Pacira BioSciences, Inc. (PCRX): R&D Expense
$117.31M
Year ended 2025-12-31
$121.73M
Trailing 12 months to 2026-06-30
+11.4%
3-year compound annual growth
+14.6%
5-year compound annual growth
+15.1%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $117.31M | +43.8% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $81.58M | +7.0% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $76.26M | -10.1% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $84.80M | +52.7% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $55.55M | -6.5% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $59.42M | -17.6% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $72.12M | +29.5% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $55.69M | -2.8% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $57.29M | +25.4% | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | $45.68M | +59.4% | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | $28.66M | +53.0% | 2018-02-28, From 2015-01-01 |
| 2014-12-31 | $18.73M | -13.1% | 2016-02-25, From 2014-01-01 |
| 2013-12-31 | $21.56M | +117.0% | 2016-02-25, From 2013-01-01 |
| 2012-12-31 | $9.94M | -33.2% | 2015-02-24, From 2012-01-01 |
| 2011-12-31 | $14.87M | -20.2% | 2014-02-25, From 2011-01-01 |
| 2010-12-31 | $18.63M | -29.0% | 2013-03-07, From 2010-01-01 |
| 2009-12-31 | $26.23M | n/a | 2012-03-27, From 2009-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $117.31M | +43.8% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $85.84M | +16.1% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $106.23M | -2.4% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $53.20M | -24.8% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $254.91M | +3.2% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $96.85M | -13.2% |
| Collegium Pharmaceutical, Inc (COLL) | 2024-12-31 | $0 | n/a |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $750.00M | +7.4% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $183.28M | -2.0% |
Compare PCRX, AMPH, SUPN, EBS side by side · Screen every company in Pharmaceutical Preparations ↗